Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

FINAL TERMS/UPSIZE: Cheplapharm E950m 6NC2 sr sec notes at 6.75%

HYC European Market: Commentary - General

Cheplapharm Arzneimittel GmBH EUR950m (up from EUR750m) 144A/Reg S sr sec notes due 2032 (6y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the 1st 3 years at 103. B3/B/B+ (stable/stable/stable). Via Citi/DB (D&B) jt glocos and physical books/Barc/BofA/Commerz/GS/JPM/ING/UBS/UniCredit jt books. No reg rights. List ISE. NY law. CoC at 101. Denoms: 100kx1k. IPT: 7.00%-7.25%. Price talk: 6.75%-7.00% EUR200m upsize to partially repay its sr sec term loan B due 2029.

Final terms: EUR950m at 6.75%.

Roadshow (small in person group meetings) 01/26-27 (investor call 11am UKT 01/26). Books closed at 1:30pm UKT 01/27. Reconfirms due by 3:45pm 01/27. Pricing 01/27 UK afternoon. UOP: along with EUR14m cash on hand, to refinance the existing EUR575m 4.375% sr sec notes due 01/15/28 (callable at 100) and US$215m 5.50% sr sec notes due 01/15/28 (callable at 100) (EUR200m upsize to partially repay its sr sec term loan B due 2029). Privately owned by Sebastian Braun, Co-CEO (50%), and Dr Bianca Juha, Chief Scientific Officer (50%). Biz: specialty pharmaceuticals. HQ: Greifswald, Germany.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.